[Edaily Reporter Shin Ha-yeon ] SamyangFoods(003230)is trading higher on expectations of growth driven by strong overseas sales and the start of operations at its Chinese factory.
According to MP Doctor on the 21st, SamyangFoods is trading at 1.12 million won as of 9:36 a.m. today, up 6.36% from the previous trading day.
Amid increased valuation appeal following a recent stock price correction, securities analysts’ forecasts of continued earnings improvement in the second half of the year are believed to have stimulated investor sentiment.
Yuanta Securities Korea maintained its “Buy” rating and target price of 2 million won for SamyangFoods today.
Son Hyun-jung, an analyst at Yuanta Securities Korea, projected that SamyangFoods’ second-quarter consolidated revenue would reach 761.6 billion won—a 37.7% increase year-over-year—while operating profit would rise 46.5% to 176.0 billion won. Overseas sales are estimated at 628.2 billion won, accounting for 82.5% of total revenue.
The analysis indicates that production volume increased by more than 10% compared to the previous quarter due to extended operating hours and overtime at the Miryang Plant No. 2, which supported sales growth in key regions such as the U.S., China, and Europe.
The firm projected that the improvement in earnings will be even more pronounced in the second half of the year. It is highly likely that consolidated revenue will exceed 800 billion won in the third quarter, reflecting deferred sales to the U.S. and an increase in the utilization rate at the Miryang Plant No. 2.
Analyst Son stated, “Due to the recent stock price correction, the current stock price has fallen to a level equivalent to a 2027 projected price-to-earnings ratio (PER) of 10,” adding, “Now is the time to focus on profit growth in the second half of the year and the improvement in earnings following the start of operations at the China plant.”
This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…